Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Safety, Immunogenicity and Compatibility With DTP of a Typhoid Fever Vaccine in Infants

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
ClinicalTrials.gov Identifier:
NCT00342628
First received: June 19, 2006
Last updated: May 22, 2012
Last verified: May 2012
Results First Received: March 30, 2012  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Safety Study;   Intervention Model: Parallel Assignment;   Masking: Open Label;   Primary Purpose: Prevention
Condition: Typhoid Fever
Interventions: Biological: Vi-rEPA conjugate vaccine for typhoid fever
Biological: Hib-TT
Biological: DTP

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Informed consent was obtained from expectant women during prenatal visits in Thanh Thuy District, Phu-Tho Province, Vietnam. Mothers and newborns were enrolled during labor at commune/district health centers from July 26, 2006 to March 8, 2007. Only fullterm newborns with birth weights of >=2500 grams were enrolled.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Vi-rEPA Plus DTP Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age
Hib-TT Plus DTP Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age
DTP Vaccines DTP at 2, 4, and 6 months of age

Participant Flow:   Overall Study
    Vi-rEPA Plus DTP   Hib-TT Plus DTP   DTP Vaccines
STARTED   100   101   100 
COMPLETED   80 [1]   80 [2]   81 [3] 
NOT COMPLETED   20   21   19 
Withdrawal by Subject                19                19                18 
Death                1                1                0 
moved residence                0                1                1 
[1] 84 completed 4 injections, 4 were lost-to-followup after the 4th injection
[2] 83 completed 4 injections, 3 were lost-to-followup after 4th injection
[3] 97 completed 3 injections of DTP alone, 16 were lost-to-followup for blood drawing at 12 months.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Vi-rEPA Plus DTP Vi-rEPA plus DTP at 2, 4, 6 and Vi-rEPA at 12 months of age
Hib-TT Plus DTP Hib-TT plus DTP at 2,4,6 and Hib-TT at 12 months of age
DTP Vaccines DTP at 2, 4, and 6 months of age
Total Total of all reporting groups

Baseline Measures
   Vi-rEPA Plus DTP   Hib-TT Plus DTP   DTP Vaccines   Total 
Overall Participants Analyzed 
[Units: Participants]
 100   101   100   301 
Age, Customized [1] [2] 
[Units: Days]
Mean (Full Range)
       
Age at 1st injection   77 
 (61 to 92) 
 76 
 (61 to 92) 
 76 
 (61 to 92) 
 77 
 (61 to 92) 
Age at 2nd injection   137 
 (121 to 151) 
 137 
 (120 to 154) 
 137 
 (121 to 151) 
 137 
 (120 to 154) 
Age at 3rd injection   197 
 (181 to 212) 
 198 
 (182 to 211) 
 197 
 (181 to 211) 
 197 
 (181 to 212) 
Age at 4th injection   382 
 (365 to 420) 
 381 
 (365 to 406) 
 NA [2]   382 
 (365 to 420) 
[1] Study participants are infants recruited at birth, injected with experimental and comparison vaccine at 2, 4, 6 and 12 months of age.
[2] No injection given
Gender 
[Units: Participants]
       
Female   52   53   46   151 
Male   48   48   54   150 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Infants With Adverse Reactions After Vaccination   [ Time Frame: at 2, 4, 6 and 12 months ]

2.  Secondary:   IgG Anti-Vi Levels   [ Time Frame: cord sera, infants' sera at 7, 12 and 13 months ]

3.  Secondary:   Antibody Responses to Tetanus Toxoid, Diphtheria Toxoid, and Pertussis Toxin   [ Time Frame: Cord sera, and infants' sera at 7, 12 and 13 months of age ]

4.  Secondary:   Antibody Responses to Hib CP   [ Time Frame: Cord sera and infant sera at 7, 12, and 13 months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Feng-Ying (Kimi) Lin, MD, MPH
Organization: PDMI, NICHD, NIH
phone: 301-496-0295
e-mail: link@mail.nih.gov


Publications:


Responsible Party: National Institutes of Health Clinical Center (CC) ( Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) )
ClinicalTrials.gov Identifier: NCT00342628     History of Changes
Other Study ID Numbers: 999999050
OH99-CH-N050 ( Registry Identifier: NICHD IRB )
Study First Received: June 19, 2006
Results First Received: March 30, 2012
Last Updated: May 22, 2012
Health Authority: United States: Food and Drug Administration